China NMPA Inspection - National Medical Products Administration - December 02, 2021

The Sichuan Provincial Drug Administration, through a notice dated November 19, 2021, and published on December 2, 2021, forwarded a directive from the National Medical Products Administration (NMPA). This NMPA Announcement (No. 84 of 2021) mandates the immediate cessation of sales for the cosmetic product known as "Bayuncao Fule Nursing Cream (Soothing Repair Type)." The document does not specify the direct cause for the sales halt but indicates issues requiring regulatory intervention. The regulatory framework involves the NMPA issuing the primary ban, which is then disseminated to provincial and local market supervision administrations for enforcement across China. The focus is on retailers and distributors of the affected product, rather than a single inspected company. Required actions for all market supervision bodies include intensifying inspections of businesses, ordering the immediate removal of the product from sale, meticulously examining purchase and inspection records, imposing severe penalties for any identified illegal activities, and transferring cases with suspected criminal elements to public security organs. This directive highlights the robust regulatory oversight of cosmetic products.